Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, focused on developing novel therapies for rare and ultra-rare diseases. The company was founded in 2010 by Dr. Emil D. Kakkis with a mission to bring life-changing therapies to patients who have no treatment options.

Overview

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company headquartered in Novato, California, focused on developing novel therapies for rare and ultra-rare diseases. The company was founded in 2010 by Dr. Emil D. Kakkis with a mission to bring life-changing therapies to patients who have no treatment options.

Overview

Ultragenyx specializes in developing treatments for rare genetic diseases, many of which affect the nervous system. The company uses multiple technology platforms including gene therapy, mRNA therapy, and small molecule approaches to address these unmet medical needs["@ultragenyxa"].

Funding

• IPO: 2014 (NASDAQ: RARE)
• Market Cap: ~$6B (2026)

Corporate Highlights

• Founded: 2010
• Headquarters: Novato, California
• NASDAQ: RARE
• Employees: Approximately 1,000

History and Development

Founding and Early Growth (2010-2015)

Clinical Development (2015-2020)

• 2015: Advanced first programs into clinical trials
• 2017: FDA approval of Crysvita (burosumab) for X-linked hypophosphatemia
• 2018: FDA approval of Mepsevii (vestronidase alfa) for mucopolysaccharidosis VII
• 2019: FDA approval of Dojapviz (givosiran) for acute hepatic porphyria

Recent Advances (2021-Present)

• Multiple gene therapy programs in late-stage development
• Expansion of mRNA platform
• Strategic partnerships for manufacturing

Approved Products

Crysvita (Burosumab)

• Indication: X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia
• Mechanism: FGF23 antibody
• Approval: 2017 (FDA), 2018 (EU)
• First disease: First therapy directly addressing FGF23 excess in XLH[@crysvita]

Mepsevii (Vestronidase Alfa)

• Indication: Mucopolysaccharidosis VII (Sly syndrome)
• Mechanism: Recombinant beta-glucuronidase
• Approval: 2017
• Significance: First approved therapy for this rare metabolic disorder[@mepsevii]

Dojapviz (Givosiran)

• Indication: Acute hepatic porphyria
• Mechanism: siRNA targeting ALAS1
• Approval: 2019
• Significance: First RNA interference therapy for this condition[@dojapviz]

Other Marketed Products

| Product | Indication | Mechanism |
|---------|------------|-----------|
| Evrysdi | Spinal muscular atrophy | SMN2 splicing modifier |
| Waylivra | Familial chylomicronemia syndrome | Antisense oligonucleotide |

Pipeline Programs

Gene Therapy Pipeline

| Drug Candidate | Indication | Stage | Mechanism |
|---------------|------------|-------|-----------|
| UX143 (Atidarsagene autotemcel) | MPS IIIA (Sanfilippo A) | Phase 2/3 | AAV gene therapy |
| UX007 (Triheptanoin) | Long-chain fatty acid oxidation disorders | Approved (2023) | Medium-chain triglyceride |
| UX071 | PKU | Preclinical | Gene therapy |

Neurology-Focused Programs

| Drug Candidate | Indication | Stage | Mechanism |
|---------------|------------|-------|-----------|
| UX143 | Sanfilippo syndrome A | Phase 2/3 | AAV gene therapy |
| UX053 | GLUT1 deficiency | Phase 1/2 | Gene therapy |

Neurological Relevance

Ultragenyx addresses several rare neurological and neurodegenerative conditions[@ultragenyxb]:

Sanfilippo Syndrome Type A (MPS IIIA)

Sanfilippo syndrome is a lysosomal storage disorder causing severe neurodegeneration in children:

• Cause: Deficiency in sulfamidase enzyme
• Symptoms: Developmental regression, seizures, behavioral problems
• UX143: AAV gene therapy delivering functional sulfamidase gene
• Goal: Slow or halt disease progression in early-stage patients

GLUT1 Deficiency Syndrome

GLUT1 deficiency causes seizures and movement disorders due to impaired glucose transport into the brain:

• UX053: Gene therapy to restore GLUT1 function
• Potential: Could address both seizures and movement symptoms

Other Neurological Programs

• MPS I (Hurler syndrome): Gene therapy in development
• PKU (Phenylketonuria): Gene therapy approach
• Rett syndrome: mRNA therapy research

Science and Technology

Gene Therapy Platform

• AAV9: Crosses blood-brain barrier for CNS applications
• Direct CNS delivery: Intrathecal administration
• Potential for lasting effect: Single treatment may provide long-term benefit

mRNA Technology

• Protein replacement: Deliver mRNA encoding functional proteins
• Repeat dosing: May allow treatment adjustment
• Manufacturing scale: mRNA production can be scaled efficiently

mRNA Technology

• LIPID NANOPARTICLE delivery systems
• Repeat dosing capabilities
• Potential for protein replacement in enzyme deficiencies

Financial Highlights (2024)

• Revenue: Approximately $400 million USD
• Market Cap: Approximately $3 billion USD
• R&D Investment: Approximately $400 million USD
• Key Investors: Baker Bros. Advisors, FMR LLC

Partnerships

Ultragenyx has established strategic partnerships:

• Regeneron: mRNA therapy collaboration
• Kyowa Kirin: Crysvita commercialization partnership
• Multiples academic collaborations: For rare disease research
• [Sanfilippo Syndrome](/diseases/sanfilippo-syndrome)
• GLUT1 Deficiency
• [Mucopolysaccharidosis](/genes/ar)
• [Gene Therapy](/therapeutics/gene-therapy)
• [AAV Vector](/therapeutics/aav-vectors-neurodegenerative-gene-therapy)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• X-Linked Hypophosphatemia
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/genes/ar)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References